Lyles Patients
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): A 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
These products are not approved for medical, diagnostic, or therapeutic use, and no instructions for preparation, administration, or dosage are provided
"We think that some of these people may be changing behavior, nutrition, lifestyle, [and] also may be changing the hormones in their body by being on [GLP-1 medications], changing how their brain sort of operates or functions permanently," Narula said
PMID: 36246401
Some patients and providers use 2-week or even weekly escalations to reach therapeutic dose faster